Sugi Predict

Sugi Predict / Compounds / SCHEMBL30029352

SCHEMBL30029352

SCHEMBL30029352

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 11/20 0.67
▸ CXCR4 P61073 1/20 0.65
▸ PTH1R Q03431 5/20 0.64
▸ RXFP1 Q9HBX9 1/20 0.64
▸ GCGR P47871 7/20 0.64
▸ GIPR P48546 5/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30029354 0.99 GLP1R (0.68) GLP1RCXCR4PTH1RGCGRGIPR
SCHEMBL30029149 0.99 GLP1R (0.68) GLP1RCXCR4PTH1RGCGRGIPR
SCHEMBL31182694 0.94 CXCR4 (0.71) GLP1RCXCR4PTH1RGCGR
SCHEMBL30029549 0.94 GLP1R (0.76) GLP1RGCGRGIPR
SCHEMBL30028893 0.93 GLP1R (0.71) GLP1RGCGRGIPR
SCHEMBL29922398 0.92 GLP1R (0.69) GLP1RCXCR4PTH1RRXFP1GCGR
SCHEMBL30473776 0.92 GLP1R (0.75) GLP1RGCGRGIPR
SCHEMBL30473787 0.92 GLP1R (0.75) GLP1RGCGRGIPR
SCHEMBL30536952 0.92 GLP1R (0.70) GLP1RPTH1RGCGRGIPR
SCHEMBL31759052 0.92 GLP1R (0.75) GLP1RPTH1RGCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383605-B2 Exenatide analog and use thereof ANYGEN CO., LTD. (KR) 2025-08-12 — — US disclosed
CN-115380043-A Exenatide analogue and application thereof 安医健有限公司 2022-11-22 — — CN disclosed
US-20220323548-A1 EXENATIDE ANALOG AND USE THEREOF ANYGEN CO., LTD., (KR) 2022-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12383605-B2 Exenatide analog and use thereof GLP1R, IAPP, GIPR GLP1R 1/4885CXCR4 231/4885PTH1R 290/4885
US-20220323548-A1 EXENATIDE ANALOG AND USE THEREOF GLP1R, IAPP, GIPR GLP1R 1/4885CXCR4 231/4885PTH1R 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback